• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Merck

Merck

Merck & Co Inc MRK

Last Price$55.88Day Change (%)-3.12%
Open Price$56.04Day Change ($)-1.80
Day Range55.77–57.0752-Week Range45.69–60.07

As of Fri 6/24/2016 7:37:00 PM | USD

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  6. Research
  1. Results of Phase 2 Study of Merck ’s Investigational Beta-Lactamase Inhibitor Relebactam in Combination with Imipenem/Cilastatin Presented at ASM Microbe

    Results of Phase 2 Study of Merck ’s Investigational Beta-Lactamase Inhibitor Relebactam in Combination with Imipenem/Cilastatin Presented at ASM Microbe

  2. Merck to purchase biotech Afferent for at least $500 million

    Merck to purchase biotech Afferent for at least $500 million

  3. Merck and Pfizer Announce Two Pivotal Phase 3 Studies for Ertugliflozin, an Investigational SGLT-2 Inhibitor, Met Primary Endpoints, Showing Significant A1C Reductions in Patients with Type 2 ...

    Merck and Pfizer Announce Two Pivotal Phase 3 Studies for Ertugliflozin, an Investigational SGLT-2 Inhibitor, Met Primary Endpoints, Showing Significant A1C Reductions in Patients with Type 2 Diabetes

  4. Bayer CEO Takes Risk in Bid for Monsanto

    Bayer CEO Takes Risk in Bid for Monsanto

  5. Global Hypercholesterolemia Pipeline Report 2016 - Therapeutics Review of 36 Companies & Drug Profile Activity - Research and Markets

    Global Hypercholesterolemia Pipeline Report 2016 - Therapeutics Review of 36 Companies & Drug Profile Activity - Research and Markets

  6. S&P 500's technical backdrop remains -2-

    S&P 500's technical backdrop remains -2-

  7. S&P 500's technical backdrop remains bullish-leaning pending Brexit vote

    S&P 500's technical backdrop remains bullish-leaning pending Brexit vote

  8. UPDATE: U.S. stocks try to extend gains to 3rd day ahead of Brexit vote

    UPDATE: U.S. stocks try to extend gains to 3rd day ahead of Brexit vote

  9. This Vanguard Fund Is Conservatism at Its Best

    Gold-rated Vanguard Wellesley Income's management, proven strategy, and rock-bottom fees inspire confidence for the long term.

  10. Chemotherapy Induced Nausea & Vomiting Global Clinical Trials Review, H1, 2016 - Analysis, Technologies & Forecasts - Key Vendors: Merck , Tesaro, Eisai - Research and Markets

    Chemotherapy Induced Nausea & Vomiting Global Clinical Trials Review, H1, 2016 - Analysis, Technologies & Forecasts - Key Vendors: Merck , Tesaro, Eisai - Research and Markets

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.